The use of sodium sodium sambatane in Zolasilin requires a combination of factors including the age of the patient, the severity of the condition, the type of infection and the kidney function.
1. Adult use (i) intravenous dripping 1. General infections For moderately infected persons, the usual dose is Zolacillin 3 – 4g and Shubathan 1.5 – 2g, every 6 – 8 hours. For example, in the treatment of pure urinary infections, this dosage programme allows drugs to maintain effective antibacterial concentrations in blood and urinary systems and inhibits the growth and reproduction of pathogens. Dissolve the drug in an appropriate amount of dilution (e.g. 0.9% sodium chloride or 5% glucose injection) with slow intravenous dripping, which generally takes no less than 30 minutes. This reduces the vascular irritation of the drug while facilitating its equal distribution in the body. • The dose may be increased, as appropriate, in the treatment of serious infections, such as hospital access to sexually transmitted pneumonia, complex abdominal infections, etc. In general, Zolacirin 4 – 6g and Shubathan 2 – 3g, every 4 – 6 hours. This is due to the fact that, in the case of severe infections, pathogens are more numerous and toxic and require higher drug concentrations to control the infection quickly. The high level of drug concentrations in blood can be sustained above the level of effective microbicides through frequent delivery and increased doses. There is also a need for slow intravenous dripping after the drug has been dissolved, during which the patient ‘ s response is closely observed, and to prevent adverse effects such as a fluid response. (ii) Muscular injection • Although intravenous dripping is a more common method of delivery, muscle injection may be considered in certain special cases when the patient is unable to inject. Muscle injections were typically 2 – 4g and 1 – 2g in Zolacirin, 2 – 4 times a day. However, as muscle injections can cause local pains, corrosiveness, etc., attention should be paid to the selection of injection sites and injection techniques during the operation to minimize the discomfort of patients.
The amount of sodium sodium sambatane used by children is usually calculated on the basis of weight. For infants and children, the general dose is 100 – 200 mg/kg per day for Zolacillin and 50 – 100 mg/kg per day for Shubathan, at 2 – 3 times. For example, for a child with a body weight of 10 kg, the daily dose of Zolacillin is about 1-2g, and the daily dose of Shubathan is about 0.5-1g, with two to three intravenous drops. Special attention should be paid to the control of drip speed during intravenous dripping, as children ‘ s heart and vascular systems are fragile and excessive velocity can lead to serious consequences such as heart failure. At the same time, it is important to monitor closely whether children have adverse reactions such as allergies, as children ‘ s immune systems are not yet fully developed and are more susceptible to drug sensitization. 2. Muscle injection (lower use) • If muscle injection is required, dosages are also calculated on the basis of body weight, but are usually used as a sub-pharmaceutical method because muscle injection may cause more pain and local adverse effects in children. The dose range is 80 – 160 mg/kg and 40 – 80 mg/kg per day in Shubatán, 2 – 4 times.
iii. The amount of use of kidney reduction patients needs to be adjusted to the extent of kidney impairment for patients with kidney impairment. Since Zolasicillin and Shubathan are excreted mainly through kidneys, when renal function is impaired, the rate at which drugs are excreted in the body is reduced, which can easily lead to drug accumulation and increase the risk of adverse effects. The kidney function is generally assessed by testing the patient ‘ s acetic anhydride removal rate. When the acetic anhydride removal rate is less than 20 ml/min, the interval between the drugs needs to be extended and the dose may need to be reduced appropriately. Specific adjustment programmes require a comprehensive medical assessment of the patient ‘ s kidney function and condition to ensure that the adverse effects of the drug on the patient are minimized while effectively treating the infection.
